Trial Profile
Phase II Trial of Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 14 Mar 2022 Planned initiation date changed from 1 Dec 2020 to 1 Apr 2022.
- 25 Oct 2020 Planned End Date changed from 1 May 2020 to 1 May 2023.
- 25 Oct 2020 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2023.